An Evaluation of a SVA Retrotransposon in the FUS Promoter as a Transcriptional Regulator and Its Association to ALS

• Abigail L. Savage ,

  Contributed equally to this work with: Abigail L. Savage, Thomas P. Wilm

  Affiliation Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, The University of Liverpool, Liverpool, United Kingdom

  ⨯
• Thomas P. Wilm ,

  Contributed equally to this work with: Abigail L. Savage, Thomas P. Wilm

  Affiliation Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, The University of Liverpool, Liverpool, United Kingdom

  ⨯
• Kejhal Khursheed ,

  ¶These authors also contributed equally to this work.

  Affiliation Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, The University of Liverpool, Liverpool, United Kingdom

  ⨯
• Aleksey Shatunov,

  Affiliation Clinical Neuroscience, Institute of Psychiatry, King's College London, London, United Kingdom

  ⨯
• Karen E. Morrison,

  Affiliation School of Clinical and Experimental Medicine, College of Medicine and Dentistry, University of Birmingham, Birmingham, United Kingdom; and Neurosciences Division, University Hospital Birmingham NHS Foundation Trust, Birmingham, West Midlands, United Kingdom

  ⨯
• Pamela J. Shaw,

  Affiliation Academic Unit of Neurology, Department of Neuroscience, Sheffield Institute for Translational Research, University of Sheffield, Sheffield, South Yorkshire, United Kingdom

  ⨯
• Christopher E. Shaw,

  Affiliation Clinical Neuroscience, Institute of Psychiatry, King's College London, London, United Kingdom

  ⨯
• Bradley Smith,

  Affiliation Clinical Neuroscience, Institute of Psychiatry, King's College London, London, United Kingdom

  ⨯
• Gerome Breen,

  Affiliation MRC Social Genetic and Developmental Psychiatry Research Centre, Institute of Psychiatry, King's College London, London, United Kingdom; National Institute for Health Research Biomedical Research, Centre for Mental Health, South London, United Kingdom; and Maudsley NHS Foundation Trust and Institute of Psychiatry, King's College London, London, United Kingdom

  ⨯
• Ammar Al-Chalabi,

  Affiliation Clinical Neuroscience, Institute of Psychiatry, King's College London, London, United Kingdom

  ⨯
• Diana Moss,

  Affiliation Department of Cellular and Molecular Physiology, Institute of Translational Medicine, The University of Liverpool, Liverpool, United Kingdom

  ⨯
• Vivien J. Bubb,

  Affiliation Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, The University of Liverpool, Liverpool, United Kingdom

  ⨯
• John P. Quinn

  * E-mail: jquinn@liv.ac.uk

  Affiliation Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, The University of Liverpool, Liverpool, United Kingdom

  ⨯